A Phase 1 interventional study of Hyperpolarized Pyruvate (13C) and Magnetic Resonance Spectroscopic Imaging (MRSI) in Glioblastoma, Recurrent Glioblastoma and Glioblastoma Multiforme, sponsored by Susan Chang. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Susan Chang · Phase 1, Interventional, and Diagnostic
Slow Accrual
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 835th largest by enrollment of the 1,156 interventional ones that give a count, is one of 49 that started in 2019, is one of 482 in phase 1, and was the 931st registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,303 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 672 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 49 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,156 interventional studies, 60 across the 79 observational. Of the 883 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,303 have an industry lead sponsor. The 10 most frequent:
Susan Chang is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Susan Chang has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
104 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 104 to your calendar (.ics) → With an account.
Among the 1,303 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future.
If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized pyruvate 13C, to obtain dynamic metabolic imaging.
PRIMARY OBJECTIVES:
I. To evaluation safety of hyperpolarized (HP) pyruvate (13C) injection for use in imaging lesions in participants with glioblastoma (GBM).
II. To evaluate metabolic changes in tumors and normal-appearing brain tissue in response to standard therapy.
EXPLORATORY OBJECTIVES:
I. To evaluate changes in 13C parameters from baseline to the post-RT scan compared in the normal appearing brain, enhancing lesion, non-enhancing lesion and the choline-to-N -acetyl aspartate (NAA) index (CNI) lesion.
II. To evaluate 13C metabolic parameters from the recurrent lesions compared to those in the regions of treatment related effects.
III. To evaluate 13C and 1H metabolic parameters to determine the association to time to progression and overall survival.
OUTLINE:
Participants are assigned to 3 cohorts based on disease status and non-investigational treatment plan. All participants enrolled in the study will receive at least 1 hyperpolarized pyruvate (13C) injection.
COHORT 1: Participants with newly diagnosed glioblastoma who will undergo standard of treatment with radiotherapy and temozolomide (TMZ). Magnetic resonance spectroscopic imaging (MRSI) imaging will occur at 2 time points: Before receiving non-investigational treatment with radiation and chemotherapy, and at the first post-radiation follow-up scan. Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as a standard MR.
COHORT 2: Participants with recurrent, suspected GBM who will receive non-investigational surgical resection. MRSI imaging with hyperpolarized 13C pyruvate injection will occur at a single time point before surgery.
COHORT 3: Participants with recurrent suspected GBM who will undergo non-investigational standard treatment will have three MR examination time points. Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as standard MR. The MR examinations will occur prior to initiating therapy (baseline), at approximately 7-14 days after initiation of therapy, and 6-8 weeks after the initiation of therapy.
Participants will be follow-up for up to 2 months after completion of non-investigational treatment, and for 7 days after final injection of hyperpolarized 13C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is for participants with histologically proven newly diagnosed glioblastoma who will undergo non-investigational treatment with radiation therapy (RT) and temozolomide (TMZ). Participants will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (4-8 weeks later).
Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)
This arm is for participants with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence. Participants will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery.
Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)
This arm is for participants with histologically proven recurrent suspected who will undergo standard treatment for the recurrence. Participants will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment.
Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)
Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each MRSI procedure.
Also known as: HP-13C
Undergo MRSI
Also known as: MRSI
Number of Treatment Emergent Adverse Events (AEs)
Participants will be monitored for the occurrence of treatment-emergent AEs assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration until 7 days after administration. Serious adverse events occurring after 7 days after administration need only be reported if relationship to the investigational drug is suspected. The number of overall treatment emergent adverse events that occur will be reported for each cohort.
Time frame: From Day 1 through study completion, up to 4 months
Number of Dose-Limiting Toxicities (DLTs)
A DLT for this protocol is defined as any event grade 3 or higher in severity assessed by the NCI CTCAE version 4.0 that is possibly, probably, or definitely attributable to the investigational drug, excluding laboratory abnormalities determined to be clinically insignificant. The number of DLTs for each cohort will be reported.
Time frame: From Day 1 through study completion, up to 4 months
Mean Change in 13C Pyruvate-to-Lactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)
The mean change in 13C kPL from baseline to the post-RT scan will be calculated for normal appearing brain and tumor(s) (lesions) for Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.
Time frame: Up to 8 weeks
Mean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)
The mean changes in 13C lactate/pyruvate ratio from baseline to the post-RT scan will be compared in the normal appearing brain and tumor(s) (lesions) for participants in Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.
Time frame: Up to week 8
| Milestone | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|---|
| Started | 15 | 1 | 1 |
| Completed | 13 | 1 | 1 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Scan determined to be non-evaluable by investigators | 2 | 0 | 0 |
| Milestone | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|---|
| Started | 13 | 0 | 1 |
| Completed | 4 | 0 | 0 |
| Not completed | 9 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 |
| Withdrew: Scan not obtained or determined to be non-evaluable by investigators | 3 | 0 | 1 |
Participants will be monitored for the occurrence of treatment-emergent AEs assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration until 7 days after administration. Serious adverse events occurring after 7 days after administration need only be reported if relationship to the investigational drug is suspected. The number of overall treatment emergent adverse events that occur will be reported for each cohort.
| treatment-emergent adverse events | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (AEs) | 0 | 0 | 0 |
A DLT for this protocol is defined as any event grade 3 or higher in severity assessed by the NCI CTCAE version 4.0 that is possibly, probably, or definitely attributable to the investigational drug, excluding laboratory abnormalities determined to be clinically insignificant. The number of DLTs for each cohort will be reported.
| dose-limiting toxicities | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|---|
| Number of Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 |
The mean change in 13C kPL from baseline to the post-RT scan will be calculated for normal appearing brain and tumor(s) (lesions) for Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.
| 1/seconds | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|
| Lesion | -24.1 (-61.8 to 1.6) | — |
| Normal appearing brain | 1.9 (-4 to 10.9) | — |
The mean changes in 13C lactate/pyruvate ratio from baseline to the post-RT scan will be compared in the normal appearing brain and tumor(s) (lesions) for participants in Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.
| change in lactate/pyruvate ratio | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment |
|---|---|---|
| Lesion | -38.6 (-78.2 to -10.2) | — |
| Normal appearing brain | -4.6 (-19.9 to 8.5) | — |
Collected over Up to 4 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Newly Diagnosed Glioblastoma | 1/15 (6.7%) | 0/15 (0%) | 0/15 (0%) |
| Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
All enrolled participants will be included in safety analysis.
| Age, Customized(Participants) | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | Total |
|---|---|---|---|---|
| 20-29 years old | 1 | NA | NA | NA |
| 30-39 years old | 0 | NA | NA | NA |
| 40-49 years old | 2 | NA | NA | NA |
| 50-59 years old | 6 | NA | NA | NA |
| 60-69 years old | 5 | NA | NA | NA |
| 70-79 years old | 1 | NA | NA | NA |
| Sex: Female, Male(Participants) | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | Total |
|---|---|---|---|---|
| Female | 4 | NA | NA | NA |
| Male | 11 | NA | NA | NA |
| Race (NIH/OMB)(Participants) | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | NA | NA | NA |
| Asian | 1 | NA | NA | NA |
| Native Hawaiian or Other Pacific Islander | 0 | NA | NA | NA |
| Black or African American | 0 | NA | NA | NA |
| White | 14 | NA | NA | NA |
| More than one race | 0 | NA | NA | NA |
| Unknown or Not Reported | 0 | NA | NA | NA |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | NA | NA | NA |
| Not Hispanic or Latino | 14 | NA | NA | NA |
| Unknown or Not Reported | 0 | NA | NA | NA |
| Region of Enrollment(Participants) | Cohort 1: Newly Diagnosed Glioblastoma | Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection | Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment | Total |
|---|---|---|---|---|
| United States | 15 | 1 | 1 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2019 to primary completion in Sep 2025, 70 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
Slow Accrual
Slow Accrual
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyperpolarized Carbon C 13 (1-13C) Pyruvate
Susan Chang